Related Experiment Video

Updated: May 26, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

STAT3 inhibitor in oncology: a trial-based analysis of translational challenges and evolving therapeutic paradigms

Siyuan Yang1, Lei Wang2, Zhirui Chuan3

  • 1Department of Breast Surgery, Peking University Cancer Hospital Yunnan Hospital, Yunnan Cancer Hospital, Third Affiliated Hospital, Kunming Medical University, Kunming, Yunnan, China.

Frontiers in Oncology
|May 25, 2026
PubMed

Insights

Clinical trials for Signal Transducer and Activator of Transcription 3 (STAT3) inhibitors peaked in 2018 and declined due to challenges. Future strategies focus on novel inhibitors and biomarker-guided selection for effective cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trial Analysis

Background:

  • Signal Transducer and Activator of Transcription 3 (STAT3) is a critical oncogenic target.
  • Clinical development of STAT3 inhibitors faces significant hurdles.
  • Previous strategies focused on Src homology 2 (SH2) domain inhibition.

Purpose of the Study:

  • To analyze the developmental patterns of STAT3 inhibitors in oncology clinical trials.
  • To identify challenges and evolving strategies in STAT3-targeted cancer therapy.
  • To provide insights for future clinical development.

Main Methods:

  • Systematic retrospective analysis of oncology trials from the Trialtrove database.
  • Identification and analysis of 130 eligible trials.
  • Examination of trial trends, attrition reasons, and emerging therapeutic strategies.

Main Results:

  • The number of STAT3 inhibitor trials peaked in 2018 and declined post-2019.
  • Phase III attrition was attributed to efficacy-safety issues and enrollment difficulties.
  • A paradigm shift is occurring towards next-generation inhibitors (coiled-coil domain, mitochondrial STAT3) and biomarker-guided approaches.

Conclusions:

  • Advancing STAT3-targeted cancer therapy requires overcoming clinical development challenges.
  • Biomarker-guided patient selection and innovative, specific inhibitors are crucial.
  • Optimized trial strategies are needed to bridge the gap between preclinical research and clinical application.
Keywords:
STAT3 inhibitorcancer therapyclinical trialsmolecular targeted therapytranslational medicine

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...